Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, P.R. China
✉ Corresponding authors: Baoan Chen, Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Dingjiaqiao 87, Gulou District, Nanjing 210009, Jiangsu Province, P.R. China. Tel: +86 25 83272006, Fax: +86 25 83272011. E-mail: cba8888com. Runzhe Chen, Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Dingjiaqiao 87, Gulou District, Nanjing 210009, Jiangsu Province, P.R. China. E-mail: runzhe.chenedu.cn. Xiaoping Zhang, Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Dingjiaqiao 87, Gulou District, Nanjing 210009, Jiangsu Province, P.R. China. E-mail: zhangxiaopingseucomMore
Citation:
Chen R, Wang Y, Luan C, Gao C, Zhang X, Chen B. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer 2017; 8(10):1801-1808. doi:10.7150/jca.17999. https://www.jcancer.org/v08p1801.htm
In this work, we aim to further analyze the effect of pomalidomide for relapsed and/or refractory multiple myeloma (RRMM). A systematic literature search of PubMed, MEDLINE and EMBASE was conducted on September 20, 2016. Pooled effect size (ES) with corresponding 95% confidence intervals (CIs) were calculated using random-effects model. STATA software (version 12.0; Stata Corporation; College Station, TX, USA) was employed to do all statistical analyses. A total of 8 studies were included for analysis. The combined results demonstrated that the pooled proportion of overall response rate (ORR) was 0.35 (95% CI 0.27 to 0.43, P=0.000), and the pooled proportion of complete response rate (CRR) was 0.02 (95% CI 0.01 to 0.03, P=0.541). Pomalidomide was generally well tolerated by patients reported in the studies. Further studies would be required to conduct more prospective randomized controlled trials (RCTs) with larger samples to assess the proper place of pomalidomide as single agent or combined with other agents for RRMM.
Chen, R., Wang, Y., Luan, C., Gao, C., Zhang, X., Chen, B. (2017). Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Journal of Cancer, 8(10), 1801-1808. https://doi.org/10.7150/jca.17999.
ACS
Chen, R.; Wang, Y.; Luan, C.; Gao, C.; Zhang, X.; Chen, B. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J. Cancer 2017, 8 (10), 1801-1808. DOI: 10.7150/jca.17999.
NLM
Chen R, Wang Y, Luan C, Gao C, Zhang X, Chen B. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer 2017; 8(10):1801-1808. doi:10.7150/jca.17999. https://www.jcancer.org/v08p1801.htm
CSE
Chen R, Wang Y, Luan C, Gao C, Zhang X, Chen B. 2017. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer. 8(10):1801-1808.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.